biopreparatБИОпрепараты. Профилактика, диагностика, лечениеBiological Products. Prevention, Diagnosis, Treatment2221-996X2619-1156Scientific Centre for Expert Evaluation of Medicinal Productsbiopreparat-85Research ArticleОБЗОРЫREVIEWSГемофильная инфекция типа b. Заболеваемость и вакцинопрофилактикаHaemophilus influenzae type b. Incidence rate and preventive vaccinationАбрамцеваМ. В.AbramtsevaM. V.

Ведущий эксперт лаборатории бактериальных вакцин Испытательного центра экспертизы качества МИБП,

127051, Москва, Петровский бульвар, 8, стр. 2

Leading expert of the Laboratory of Bacterial Vaccines of the Testing Centre for Evaluation of Medicinal Immunobiological Products’ Quality,

Petrovsky boulevard 8, bld. 2, Moscow 127051

noemail@neicon.ruТарасовА. П.TarasovA. P.

эксперт 1-й категории лаборатории бактериальных вакцин Испытательного центра экспертизы качества МИБП, канд. биол. наук,

127051, Москва, Петровский бульвар, 8, стр. 2

1st professional category expert of the Laboratory of Bacterial Vaccines of the Testing Centre for Evaluation of Medicinal Immunobiological Products’ Quality. Candidate of Biological Sciences,

Petrovsky boulevard 8, bld. 2, Moscow 127051

noemail@neicon.ruНемировскаяТ. И.NemirovskayaT. I.

Начальник лаборатории бактериальных вакцин Испытательного центра экспертизы качества МИБП, канд. мед. наук,

127051, Москва, Петровский бульвар, 8, стр. 2

Head of the Laboratory of Bacterial Vaccines of the Testing Centre for Evaluation of Medicinal Immunobiological Products’ Quality. Candidate of Medical Sciences,

Petrovsky boulevard 8, bld. 2, Moscow 127051

noemail@neicon.ruКовтунВ. П.KovtunV. P.

Ведущий эксперт лаборатории бактериальных вакцин Испытательного центра экспертизы качества МИБП, канд. мед. наук,

127051, Москва, Петровский бульвар, 8, стр. 2

Leading expert of the Laboratory of Bacterial Vaccines of the Testing Centre for Evaluation of Medicinal Immunobiological Products’ Quality. Candidate of Medical Sciences,

Petrovsky boulevard 8, bld. 2, Moscow 127051

noemail@neicon.ruВолковВ. А.VolkovV. A.

ксперт 2-й категории лаборатории бактериальных вакцин Испытательного центра экспертизы качества МИБП,

127051, Москва, Петровский бульвар, 8, стр. 2

2nd professional category expert of the Laboratory of Bacterial Vaccines of the Testing Centre for Evaluation of Medicinal Immunobiological Products’ Quality,

Petrovsky boulevard 8, bld. 2, Moscow 127051

noemail@neicon.ruМовсесянцА. А.MovsesyantsA. A.

Начальник Испытательного центра экспертизы качества МИБП, д-р мед. наук, профессор,

127051, Москва, Петровский бульвар, 8, стр. 2

Head of the Testing Centre for Evaluation of Medicinal Immunobiological Products’ Quality. Doctor of Medical Sciences, professor,

Petrovsky boulevard 8, bld. 2, Moscow 127051

noemail@neicon.ruНаучный центр экспертизы средств медицинского примененияРоссияScientific Centre for Expert Evaluation of Medicinal ProductsRussian Federation2017200220181727886Copyright © Абрамцева М.В., Тарасов А.П., Немировская Т.И., Ковтун В.П., Волков В.А., Мовсесянц А.А., 20182018Абрамцева М.В., Тарасов А.П., Немировская Т.И., Ковтун В.П., Волков В.А., Мовсесянц А.А.Abramtseva M.V., Tarasov A.P., Nemirovskaya T.I., Kovtun V.P., Volkov V.A., Movsesyants A.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.biopreparations.ru/jour/article/view/85

В статье изложены современные представления об инфекции, вызываемой Haemophilus influenzae типа b (Hib-инфекция). Рассмотрены клинико-иммунологические особенности вакцинации против Hib-инфекции. Представлены данные о заболеваемости инвазивными формами Hib-инфекции в Российской Федерации и в разных странах мира. Особое внимание уделено вакцинопрофилактике Hib-инфекции. Дана характеристика полисахаридных и конъюгированных Hib-вакцин. Рассмотрены различные схемы иммунизации, медицинские показания и противопоказания к применению, возможные побочные реакции, а также порядок проведения вакцинации.

The article summarizes the existing knowledge on the infection caused by Haemophilus influenzaetypeb (Hib-infection). It examines clinical immunology aspects of vaccination against Hib-infection. The authors cite data on the incidence of invasive Hib-infections in the Russia and other countries. Special attention is given to preventive vaccination against Hib-infection. The article describes properties of polysaccharide and conjugate vaccines against Hib-infection and examines different immunization schedules, therapeutic indications and contraindications, potential adverse reactions, and the vaccination procedure.

гемофильная инфекция типа b (Hib-инфекция)капсульные полисахаридывакцинопрофилактикакалендарь прививокполирибозилрибитолфосфат (PRP)полисахаридные вакциныконъюгированные вакциныкомбинированные вакциныhaemophilus influenzae type b (Hib-infection)capsular polysaccharidespreventive vaccinationimmunization schedulepolyribosylribitolphosphate (PRP)polysaccharide vaccinesconjugate vaccinescombination vaccinesReferencesHaemophilus influenzae bacteria. NIBSC/SCIENCE PHOTO LIBRARY. Available from: http://www.sciencephoto.com/media/ 11458/view.Haemophilus influenzae bacteria. NIBSC/SCIENCE PHOTO LIBRARY. Available from: http://www.sciencephoto.com/media/11458/view.Богданович ТМ, Стецюк ОУ, Кречикова OИ, Боронина ЛГ, Катосова ЛК, Фаустова МЕ. Страчунский ЛС, ред. Выделение, идентификация и определение чувствительности к антибиотикам Haemophilus influenzae. Клиническая микробиология и антимикробная химиотерапия 2000; 2(2): 93-109.Bogdanovich TM, Stecjuk OU, Krechikova OI, Boronina LG, Katosova LK, Faustova ME. Strachunskij LS, ed. Isolation, identification and antimicrobial susceptibility testing of Haemophilus influenzae. Clinical Microbiology and Antimicrobial Chemotherapy 2000; 2(2): 93–109 (in Russian).Pfieffer R. Die Aetiologie der Influenza. Z Hyg Infect. 1893; 13: 357-86.Pfieffer R. Die Aetiologie der Influenza. Z Hyg Infect. 1893; 13: 357–86.Epidemiology and prevention of vaccine-preventable diseases: The Pink Book: Course Textbook. 12th ed. Second Printing (May 2012). Available from: https://goo.gl/e6EOQy.Epidemiology and prevention of vaccine-preventable diseases: The Pink Book: Course Textbook. 12th ed. Second Printing (May 2012). Available from: https://goo.gl/e6EOQy.Tognotti E. Scientific triumphalism and learning from facts: bacteriology and the «Spanish flu» challenge of 1918. Soc Hist Med. 2003; 16(1): 97-110.Tognotti E. Scientific triumphalism and learning from facts: bacteriology and the «Spanish flu» challenge of 1918. Soc Hist Med. 2003; 16(1): 97–110.Haemophilus influenzae type b (Hib) Vaccination Position Paper. WHO. Weekly epidemiological record 2013; 88(39): 413-28.Haemophilus influenzae type b (Hib) Vaccination Position Paper. WHO. Weekly epidemiological record 2013; 88 (39): 413–28.Watt JP, Wolfson LJ, O’Brien KL, Henkle E, Deloria-Knoll M, McCall N, et al. Burden of disease caused by Haemophilus influenzae type b in children younger than 5 years: global estimates. Lancet 2009; 374(9693): 903-11.Watt JP, Wolfson LJ, O’Brien KL, Henkle E, Deloria-Knoll M, McCall N, et al. Burden of disease caused by Haemophilus influenzae type b in children younger than 5 years: global estimates. Lancet 2009; 374(9693): 903–11.Moxon ER, Kroll JS. The role of bacterial polysaccharide capsules as virulence factors. Curr Top Microbiol Immunol. 1990; 150: 65-85.Moxon ER, Kroll JS. The role of bacterial polysaccharide capsules as virulence factors. Curr Top Microbiol Immunol. 1990; 150: 65–85.Crisel RM, Baker RS, Dorman DE. Capsular polymer of Haemophilus influenzae, type b. I: Structural characterization of the capsular polymer of strain Eagan. J Biol Chem. 1975; 250(13): 4926-30.Crisel RM, Baker RS, Dorman DE. Capsular polymer of Haemophilus influenzae, type b. I: Structural characterization of the capsular polymer of strain Eagan. J Biol Chem. 1975; 250(13): 4926–30.Chandran A, Watt JP, Santosham M. Haemophilus influenzae vaccines. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines, 6th ed. Philadelphia, PA, Saunders-Elsevier; 2013. P. 560-621.Chandran A, Watt JP, Santosham M. Haemophilus influenzae vaccines. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines, 6th ed. Philadelphia, PA, Saunders-Elsevier; 2013. P. 560–621.Mu XQ, Egelman EH, Bullitt E. Structure and function of Hib pili from Haemophilus influenzae type b. J Bacteriol. 2002; 184(17): 4868-74.Mu XQ, Egelman EH, Bullitt E. Structure and function of Hib pili from Haemophilus influenzae type b. J Bacteriol. 2002; 184(17): 4868–74.Briere EC, Rubin L, Moro PL, Cohn A, Clark T, Messonnier N. Prevention and control of haemophilus influenzae type b disease: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep. 2014; 63 (RR-01): 1-14.Briere EC, Rubin L, Moro PL, Cohn A, Clark T, Messonnier N. Prevention and control of haemophilus influenzae type b disease: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep. 2014; 63 (RR-01): 1–14.Fothergill LD, Wright J. Influenzal meningitis: the relation of age incidence to the bactericidal power of blood against the causal organism. J Immunol. 1933; 24: 273-84.Fothergill LD, Wright J. Influenzal meningitis: the relation of age incidence to the bactericidal power of blood against the causal organism. J Immunol. 1933; 24: 273–84.Käyhty H, Peltola H, Karanko V, Mäkelä PH. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis. 1983; 147(6): 1100.Käyhty H, Peltola H, Karanko V, Mäkelä PH. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis. 1983; 147(6): 1100.Notifiable diseases and mortality tables. Morbidity and Mortality Weekly Report (MMWR) 2015; 64(01): ND-1-ND-19. Available from: https://goo.gl/YTRlV9.Notifiable diseases and mortality tables. Morbidity and Mortality Weekly Report (MMWR) 2015; 64(01): ND-1-ND-19. Available from: https://goo.gl/YTRlV9.МР 3.3.1.0001-10 Эпидемиология и вакцинопрофилактика инфекции, вызываемой Haemophilus influenzae типа b. Методические рекомендации. 2010.MR 3.3.1.0001–10 Epidemiology and vaccine prevention of infections caused Haemophilus influenzae type b. Methodical recommendations. 2010 (in Russian).Chandrasekar PH, Cavaliere R, Rust RS, S Swaminathan. Haemophilus meningitis. Available from: https://goo.gl/NGBAEI.Chandrasekar PH, Cavaliere R, Rust RS, S Swaminathan. Haemophilus meningitis. Available from: https://goo.gl/NGBAEI.Озерецковский НА, Немировская ТИ. Вакцинация против гемофильной инфекции типа b в Российской Федерации и за рубежом. Эпидемиология и вакцинопрофилактика 2016; 15(1): 61-6.Ozeretskovsky NA, Nemirovskaya TI. Vaccination against Haemophilus influenzae type b in the Russian Federation and Abroad. Epidemiology and Vaccinal Prevention 2016; 15(1): 61–6 (in Russian).Учайкин ВФ, Шамшева ОВ, Михайлова ЕВ, Шведова НМ. Национальный календарь профилактических прививок России: проблемы и пути их решения, результаты реализации в Саратовской области (обзор). Саратовский научно-медицинский журнал 2013; 9(2): 192-6.Uchaikin VF, Shamsheva OV, Mikhailova ÅÌ, Shvedova NM. National calendar of preventive vaccination: problems, solutions and results in Saratov region. Saratov Journal of Medical Scientific Research 2013; 9(2): 192–6 (in Russian).O’Neill JM, St Geme JW 3rd, Cutter D, Adderson EE, Anyanwu J, Jacobs RF, Schutze GE. Invasive disease due to nontypeable Haemophilus influenzae among children in Arkansas. J Clin Microbiol. 2003; 41(7): 3064-9.O’Neill JM, St Geme JW 3rd, Cutter D, Adderson EE, Anyanwu J, Jacobs RF, Schutze GE. Invasive disease due to nontypeable Haemophilus influenzae among children in Arkansas. J Clin Microbiol. 2003; 41(7): 3064–9.Faden H, Duffy L, Williams A, Krystofik DA, Wolf J. Epidemiology of nasopharyngeal colonization with nontypeable Haemophilus influenzae in the first 2 years of life. J Infect Dis. 1995; 172(1): 132-5.Faden H, Duffy L, Williams A, Krystofik DA, Wolf J. Epidemiology of nasopharyngeal colonization with nontypeable Haemophilus influenzae in the first 2 years of life. J Infect Dis. 1995; 172(1): 132–5.Cochi SL, Fleming DW, Hightower AW, Limpakarnjanarat K, Facklam RR, Smith JD, et al. Primary invasive Haemophilus influenzae type b disease: a population-based assessment of risk factors. J Pediatr. 1986; 108(6): 887-96.Cochi SL, Fleming DW, Hightower AW, Limpakarnjanarat K, Facklam RR, Smith JD, et al. Primary invasive Haemophilus influenzae type b disease: a population-based assessment of risk factors. J Pediatr. 1986; 108(6): 887–96.Saha SK, Baqui AH, Darmstadt GL, Ruhulamin M, Hanif M, El Arifeen S, et al. Invasive Haemophilus influenzae type b diseases in Bangladesh, with increased resistance to antibiotics. J Pediatr. 2005; 146(2): 227-33.Saha SK, Baqui AH, Darmstadt GL, Ruhulamin M, Hanif M, El Arifeen S, et al. Invasive Haemophilus influenzae type b diseases in Bangladesh, with increased resistance to antibiotics. J Pediatr. 2005; 146(2): 227–33.Adegbola RA, Mulholland EK, Secka O, Jaffar S, Greenwood BM. Vaccination with a Haemophilus influenzae type b conjugate vaccine reduces oropharyngeal carriage of H. influenzae type b among Gambian children. J Infect Dis. 1998; 177(6): 1758-61.Adegbola RA, Mulholland EK, Secka O, Jaffar S, Greenwood BM. Vaccination with a Haemophilus influenzae type b conjugate vaccine reduces oropharyngeal carriage of H. influenzae type b among Gambian children. J Infect Dis. 1998; 177(6): 1758–61.Peltola H. Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. Clin Microbiol Rev. 2000; 13(2): 302-17.Peltola H. Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. Clin Microbiol Rev. 2000; 13(2): 302–17.Kelly DF, Moxon ER, Pollard AJ. Haemophilus influenzae type b conjugate vaccines. Immunology 2004; 113(2): 163-74.Kelly DF, Moxon ER, Pollard AJ. Haemophilus influenzae type b conjugate vaccines. Immunology 2004; 113(2): 163–74.Käyhty H, Karanko V, Peltola H, Mäkelä PH. Serum antibodies after vaccination with Haemophilus influenzae type b capsular polysaccharide and responses to reimmunization: no evidence of immunologic tolerance or memory. Pediatrics 1984; 74(5): 857-65.Käyhty H, Karanko V, Peltola H, Mäkelä PH. Serum antibodies after vaccination with Haemophilus influenzae type b capsular polysaccharide and responses to reimmunization: no evidence of immunologic tolerance or memory. Pediatrics 1984; 74(5): 857–65.Peltola H, Käyhty H, Sivonen A, Mäkelä H. Haemophilus influenzae type b capsular polysaccharide vaccine in children: a double-blind field study of 100,000 vaccinees 3 months to 5 years of age in Finland. Pediatrics 1977; 60(5): 730-7.Peltola H, Käyhty H, Sivonen A, Mäkelä H. Haemophilus influenzae type b capsular polysaccharide vaccine in children: a double-blind field study of 100,000 vaccinees 3 months to 5 years of age in Finland. Pediatrics 1977; 60(5): 730–7.Centers for Disease Control (CDC). Polysaccharide vaccine for prevention of Haemophilus influenzae type b disease. MMWR Morb Mortal Wkly Rep. 1985; 34(15): 201-5.Centers for Disease Control (CDC). Polysaccharide vaccine for prevention of Haemophilus influenzae type b disease. MMWR Morb Mortal Wkly Rep. 1985; 34(15): 201–5.Dajani AS, Asmar BI, Thirumoorthi MC. Systemic Haemophilus influenzae disease: an overview. J. Pediatr. 1979; 94(3): 355-64.Dajani AS, Asmar BI, Thirumoorthi MC. Systemic Haemophilus influenzae disease: an overview. J. Pediatr. 1979; 94(3): 355–64. 31. Avery OT, Goebel WF. Chemo-immunological studies on conjugated carbohydrate-proteins : V. The immunological specifity of an antigen prepared by combining the capsular polysaccharide of type III Pneumococcus with foreign protein. J Exp Med. 1931; 54(3): 437–47.Avery OT, Goebel WF. Chemo-immunological studies on conjugated carbohydrate-proteins : V. The immunological specifity of an antigen prepared by combining the capsular polysaccharide of type III Pneumococcus with foreign protein. J Exp Med. 1931; 54(3): 437-47.Abramtseva MV, Tarasov AP, Nemirovskaya TI. Meningococcal disease. Meningococcal conjugate polysaccharide vaccines and new generation vaccines. Report 3. BIOpreparations. Prevention, Diagnosis, Treatment 2016; 16(1): 3–13 (in Russian).Абрамцева МВ, Тарасов АП, Немировская ТИ. Менингококковая инфекция. Конъюгированные полисахаридные менингококковые вакцины и вакцины нового поколения. Сообщение 3. Биопрепараты. Профилактика, диагностика, лечение 2016; 16(1): 3-13.Granoff DM, Rathore MH, Holmes SJ, Granoff PD, Lucas AH. Effect of immunity to the carrier protein on antibody responses to Haemophilus influenzae type b conjugate vaccines. Vaccine 1993; 11(Suppl 1): S46–S51.Granoff DM, Rathore MH, Holmes SJ, Granoff PD, Lucas AH. Effect of immunity to the carrier protein on antibody responses to Haemophilus influenzae type b conjugate vaccines. Vaccine 1993; 11(Suppl 1): S46-S51.Barington T, Gyhrs A, Kristensen K. Opposite effects of actively and passively acquired immunity to the carrier on responses of human infants to a Haemophilus influenzae type b conjugate vaccine. Infect Immun. 1994; 62(1): 9–14.Barington T, Gyhrs A, Kristensen K. Opposite effects of actively and passively acquired immunity to the carrier on responses of human infants to a Haemophilus influenzae type b conjugate vaccine. Infect Immun. 1994; 62(1): 9-14.Mäkelä PH, Käyhty H, Leino T, Auranen K, Peltola H, Ekström N, Eskola J. Long-term persistence of immunity after immunisation with Haemophilus influenzae type b conjugate vaccine. Vaccine 2003; 22(2): 287–92.Mäkelä PH, Käyhty H, Leino T, Auranen K, Peltola H, Ekström N, Eskola J. Long-term persistence of immunity after immunisation with Haemophilus influenzae type b conjugate vaccine. Vaccine 2003; 22(2): 287-92.Haemophilus influenzae type b (Hib): the green book. Chapter 16. Immunization against infections desease. 2013. Available from: https://goo.gl/vYT2f3.Haemophilus influenzae type b (Hib): the green book. Chapter 16. Immunization against infections desease. 2013. Available from: https://goo.gl/vYT2f3.Canadian immunization guide: Part 4 – Active vaccines. Haemophilus influenzae type b vaccine. 2014. Available from: https://goo.gl/ qgro1Z.Canadian immunization guide: Part 4 - Active vaccines. Haemophilus influenzae type b vaccine. 2014. Available from: https://goo.gl/ qgro1Z.Haemophilus influenzae infections. Red Book. 29 ed.; Am Acad Pediatr. 2012. P. 345–52. Available from: https://goo.gl/sAmyoC.Haemophilus influenzae infections. Red Book. 29 ed.; Am Acad Pediatr. 2012. P. 345-52. Available from: https://goo.gl/sAmyoC.Adams DA, Jajosky RA, Ajani U, Kriseman J, Sharp P, Onwen DH, et al. Summary of notifiable diseases – United States, 2012. MMWR Morb Mortal Wkly Rep. 2014; 61(53): 1–121.Adams DA, Jajosky RA, Ajani U, Kriseman J, Sharp P, Onwen DH, et al. Summary of notifiable diseases - United States, 2012. MMWR Morb Mortal Wkly Rep. 2014; 61(53): 1-121.Harris JB, Gacic-Dobo M, Eggers R, Brown DW, Sodha SV. Global routine vaccination coverage, 2013. MMWR Morb Mortal Wkly Rep. 2014; 63(46): 1055–8.Harris JB, Gacic-Dobo M, Eggers R, Brown DW, Sodha SV. Global routine vaccination coverage, 2013. MMWR Morb Mortal Wkly Rep. 2014; 63(46): 1055-8.Groups with special vaccination requirements. The Australian immunization Handbook 10th, 2015. Available from: http://www.immunise.health.gov.au/7A5C97D9-EFF7-46D7-A8B8-AB0E73A4852E/ FinalDownload/DownloadId-E531F400104334DF0A8EAE21ECC5 39EA/7A5C97D9-EFF7-46D7-A8B8-AB0E73A4852E/internet/immunise/publishing.nsf/content/7B28E87511E08905CA257D4D00 1DB1F8/$File/Aus-Imm-Handbook.pdf.Groups with special vaccination requirements. The Australian immunization Handbook 10th, 2015. Available from: http://www.im- munise.health.gov.au/7A5C97D9-EFF7-46D7-A8B8-AB0E73A4852E/ FinalDownload/DownloadId-E531F400104334DF0A8EAE21ECC5 39EA/7A5C97D9-EFF7-46D7-A8B8-AB0E73A4852E/internet/im- munise/publishing.nsf/content/7B28E87511E08905CA257D4D00 1DB1F8/$File/Aus-Imm-Handbook.pdf.Washburn LK, O’Shea TM, Gillis DC, Block SM, Abramson JS. Response to Haemophilus influenzae type b conjugate vaccine in chronically ill premature infants. J Pediatr. 1993; 123(5): 791–4.Washburn LK, O’Shea TM, Gillis DC, Block SM, Abramson JS. Response to Haemophilus influenzae type b conjugate vaccine in chronically ill premature infants. J Pediatr. 1993; 123(5): 791-4.Heath PT, Booy R, McVernon J, Bowen-Morris J, Griffiths H, Slack MP, et al. Hib vaccination in infants born prematurely. Arch Dis Child. 2003; 88(3): 206–10.Heath PT, Booy R, McVernon J, Bowen-Morris J, Griffiths H, Slack MP, et al. Hib vaccination in infants born prematurely. Arch Dis Child. 2003; 88(3): 206-10.Kristensen K, Gyhrs A, Lausen B, Barington T, Heilmann C. Antibody response to Haemophilus influenzae type b capsular polysaccharide conjugated to tetanus toxoid in preterm infants. Pediatr Infect Dis J. 1996; 15(6): 525–9.Kristensen K, Gyhrs A, Lausen B, Barington T, Heilmann C. Antibody response to Haemophilus influenzae type b capsular polysaccharide conjugated to tetanus toxoid in preterm infants. Pediatr Infect Dis J. 1996; 15(6): 525-9.National Calendar of Prophylactic Immunization. Available from: https://goo.gl/CtAqe5 (in Russian).Национальный календарь профилактических прививок. Available from: https://goo.gl/CtAqe5.WHO information sheet observed rate of vaccine Haemophilus influenzae type b (Hib) vaccine. April 2012. Available from: https:// goo.gl/ezGiwx.WHO information sheet observed rate of vaccine Haemophilus influenzae type b (Hib) vaccine. April 2012. Available from: https://goo.gl/ezGiwx.Bohlke K, Davis RL, Marcy SM, Braun MM, DeStefano F, Black SB, et al. Risk of anaphylaxis after vaccination of children and adolescents. Pediatrics 2003; 112(4): 815–20.Bohlke K, Davis RL, Marcy SM, Braun MM, DeStefano F, Black SB, et al. Risk of anaphylaxis after vaccination of children and adolescents. Pediatrics 2003; 112(4): 815-20.Moro PL, Jankosky C, Menschik D, Lewis P, Duffy J, Stewart B, Shimabukuro TT. Adverse events follow Haemophilus influenzae type b vaccines in the Vaccine Adverse Event Reporting System, 1990–2013. J Pediatr. 2015; 166(4) 992–7.Moro PL, Jankosky C, Menschik D, Lewis P, Duffy J, Stewart B, Shimabukuro TT. Adverse events follow Haemophilus influenzae type b vaccines in the Vaccine Adverse Event Reporting System, 1990-2013. J Pediatr. 2015; 166(4) 992-7.MU 3.3.1.1095–02. Medical contraindications to prophylactic immunization using vaccines of the national immunization schedule. Methodology guidelines. 2002 (in Russian).МУ 3.3.1.1095-02. Медицинские противопоказания к проведению профилактических прививок препаратами национального календаря прививок. Методические указания. 2002.МУ 3.3.1.1095-02. Медицинские противопоказания к проведению профилактических прививок препаратами национального календаря прививок. Методические указания. 2002.

The authors declare that there are no conflicts of interest present.